| Cancer statistics, 2019 | Ca-A Cancer Journal for Clinicians | 2019 | 12.7K |
| Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods | International Journal of Cancer | 2019 | 3.3K |
| Cancer treatment and survivorship statistics, 2019 | Ca-A Cancer Journal for Clinicians | 2019 | 1.9K |
| Breast cancer statistics, 2019 | Ca-A Cancer Journal for Clinicians | 2019 | 1.1K |
| The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy | Nature Reviews Cancer | 2019 | 996 |
| CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012-2016 | Neuro-Oncology | 2019 | 944 |
| Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017: A Systematic Analysis for the Global Burden of Disease Study | JAMA Oncology | 2019 | 888 |
| Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial | Lancet Oncology, The | 2019 | 796 |
| Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic | Annals of Oncology | 2019 | 784 |
| Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors | World Journal of Oncology | 2019 | 734 |
| Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial | Lancet Oncology, The | 2019 | 704 |
| Epidemiology of Prostate Cancer | World Journal of Oncology | 2019 | 689 |
| Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics? | Cancer Communications | 2019 | 674 |
| Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater | Journal of Clinical Oncology | 2019 | 637 |
| The Tumor Microenvironment Innately Modulates Cancer Progression | Cancer Research | 2019 | 610 |
| Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance | Nature Reviews Clinical Oncology | 2019 | 584 |
| Targeting Ferroptosis to Iron Out Cancer | Cancer Cell | 2019 | 569 |
| Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial | Lancet Oncology, The | 2019 | 562 |
| Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology | Journal of the National Comprehensive Cancer Network: JNCCN | 2019 | 562 |
| Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up† | Annals of Oncology | 2019 | 528 |
| Cancer immunoediting and resistance to T cell-based immunotherapy | Nature Reviews Clinical Oncology | 2019 | 518 |
| Cross-Species Single-Cell Analysis of Pancreatic Ductal Adenocarcinoma Reveals Antigen-Presenting Cancer-Associated Fibroblasts | Cancer Discovery | 2019 | 479 |
| Recent advances in the mechanisms of NLRP3 inflammasome activation and its inhibitors | Cell Death and Disease | 2019 | 473 |
| Targeting PI3K in cancer: mechanisms and advances in clinical trials | Molecular Cancer | 2019 | 466 |
| Role of hypoxia in cancer therapy by regulating the tumor microenvironment | Molecular Cancer | 2019 | 447 |
